Ankylosing Spondylitis - Pipeline Insight, 2021

DelveInsight’s, “Ankylosing Spondylitis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Ankylosing Spondylitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Ankylosing Spondylitis Understanding

Ankylosing Spondylitis: Overview

Ankylosing Spondylitis (AS) is a form of arthritis that primarily affects the spine. It causes severe inflammation of the spinal joints (Vertebrae) that can lead to chronic pain and discomfort. Ankylosing Spondylitis also cause pain, inflammation in other parts of the body such as the shoulders, hips, ribs , heels and small joints of the hands and feet. In some cases, the eyes are also involved (known as iritis or uveitis). In more advanced cases, these inflammation can lead to new bone formation in the spine, causing sections of spine top fuse in fixed, immobile position. The hallmark feature of Ankylosing spondylitis is the involvement of sacroiliac (SI) joints during the progression of disease. Ankylosing Spondylitis (AS) symptoms occurs at any age, but they start occurring at the age of 45. It also affect children, called juvenile ankylosing spondylitis, and more commonly occur in boys than in girls.

""Ankylosing Spondylitis - Pipeline Insight, 2021"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ankylosing Spondylitis pipeline landscape is provided which includes the disease overview and Ankylosing Spondylitis treatment guidelines. The assessment part of the report embraces, in depth Ankylosing Spondylitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ankylosing Spondylitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Ankylosing Spondylitis R&D. The therapies under development are focused on novel approaches to treat/improve Ankylosing Spondylitis.

Ankylosing Spondylitis Emerging Drugs Chapters

This segment of the Ankylosing Spondylitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ankylosing Spondylitis Emerging Drugs
• Tofacitinib: Pfizer

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The drug is in preregistration stage for the treatment of Ankylosing spondylitis.
• Bimekizumab: UCB

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab binds to and neutralizes IL-17A and IL-17F, preventing their interactions with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts. The drug is in phase 3 development stage for the treatment of Ankylosing spondylitis.
• Namilumab: Izana Bioscience

Namilumab (IZN-101) is a monoclonal antibody therapy targeting granulocyte macrophagecolony stimulating factor (GM-CSF). IZN-101 is also in development for the treatment of rheumatoid arthritis (RA) and ankylosing spondylitis (AS), a debilitating arthritic disease with no cure. The antibody has demonstrated efficacy and safety in a phase IIb trial conducted in over 100 rheumatoid arthritis patients, and a phase II proof-of-concept study in ankylosing spondylitis is ongoing.
• KIN-1901: Kinevant Sciences

KIN-1901 is a fully human immunoglobulin monoclonal antibody (mAb) directed towards a proinflammatory cytokine that is believed to have a role in inflammation and autoimmunity, and is found in synovial fluid from patients with spondyloarthritis. Therefore, neutralization of this cytokine activity by specific monoclonal antibodies (mAbs) could be beneficial in treating certain spondyloarthropathies such as ankylosing spondylitis (AS). The drug is in phase 1 of development stage for the treatment of Ankylosing spondylitis.
• AK111: Akeso Biopharma

AK111 is a humanized IL-17 monoclonal antibody intended for the treatment of psoriasis, ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA). It is being developed by Akeso Biopharma.

Further product details are provided in the report……..

Ankylosing Spondylitis: Therapeutic Assessment

This segment of the report provides insights about the different Ankylosing Spondylitis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Ankylosing Spondylitis

There are approx. 30+ key companies which are developing the therapies for Ankylosing Spondylitis. The companies which have their Ankylosing Spondylitis drug candidates in the most advanced stage, i.e. preregistration include, Pfizer.
• Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Ankylosing Spondylitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Subcutaneous
• Intravenous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Recombinant fusion proteins
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ankylosing Spondylitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ankylosing Spondylitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ankylosing Spondylitis drugs.

Ankylosing Spondylitis Report Insights
• Ankylosing Spondylitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ankylosing Spondylitis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Ankylosing Spondylitis drugs?
• How many Ankylosing Spondylitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ankylosing Spondylitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ankylosing Spondylitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ankylosing Spondylitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Pfizer
• Amgen
• Sun Pharma Global
• Jiangsu Hengrui Medicine Co.
• Izana Bioscience
• Suzhou Zelgen
• Iltoo Pharma
• Akeso Biopharma
• Kinevant Sciences
• Qyuns Therapeutics
• Enzene Biosciences
• Xbrane Biopharma
• Dice molecules
• Mycenax Biotech
• Nimbus Therapeutics

Key Products
• Tofacitinib
• Apremilast
• Tildrakizumab
• SHR0302
• Namilumab
• Jaktinib
• AK111
• KIN-1901
• QX002N


Introduction
Executive Summary
Ankylosing Spondylitis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Ankylosing Spondylitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Ankylosing Spondylitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ankylosing Spondylitis Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
• Comparative Analysis
Tofacitinib: Pfizer
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Namilumab: Izana Bioscience
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
KIN-1901: Kinevant Sciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Ankylosing Spondylitis Key Companies
Ankylosing Spondylitis Key Products
Ankylosing Spondylitis- Unmet Needs
Ankylosing Spondylitis- Market Drivers and Barriers
Ankylosing Spondylitis- Future Perspectives and Conclusion
Ankylosing Spondylitis Analyst Views
Ankylosing Spondylitis Key Companies
Appendix
Table 1 Total Products for Ankylosing Spondylitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Ankylosing Spondylitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook